Linezolid

Linezolid Injection is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 ) Limitations of Use ( 1.6 ): ; Linezolid Injection is not indicated for the treatment of Gram-negative infections.

12.1 Mechanism of Action Linezolid is an antibacterial drug . 12.2 Pharmacodynamics In a randomized, positive- and placebo-controlled crossover thorough QT study, 40 healthy subjects were administered a single linezolid 600 mg dose via a 1 hour IV infusion, a single linezolid 1,200 mg dose via a 1 hour IV infusion, placebo, and a single oral dose of positive control. At both the 600 mg and 1,200 mg linezolid doses, no significant effect on QTc interval was detected at peak plasma concentration or at any other time.

Clinical clearance of Linezolid (Oxazolidinone Antibacterial) relies on mixed metabolic conjugation and unchanged urinary excretion across linezolid regimens with a Terminal t½ estimated at 4–8 hrs depending on renal/hepatic reserve (Linezolid) half-life; patients absorbing at F ≈ 57%–69% systemic availability after standard oral Linezolid administration bioavailability typically observe target onset around time to peak concentration spans 1 to 4 hrs under linezolid maintenance.

FDA clinical labeling for Linezolid restricts administration in 4 contraindications; known hypersensitivity to linezolid or any of the other product components.; patients taking any monoamine oxidase inhibitors (maoi) or within two weeks of taking an maoi. across 600 mg/1 Tablet, Film Coated, 600 mg/300mL Injection, Solution, 100 mg/5mL Granule, for Suspension, 100 mg/5mL Powder, for Suspension, 600 mg/1 Tablet, with self-reported patient tracking dominated by nausea (11.8% of reports), headache (10.4% of reports), diarrhea (9.1% of reports).